Overview

An Insulin Sensitivity Study in Healthy Subjects

Status:
Completed
Trial end date:
2017-07-20
Target enrollment:
Participant gender:
Summary
This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Insulin
Olanzapine